Global Dosimetry Solutions, Inc.
President Sandi Nemecek to Retire Following 34-Year Tenure;
Thomas Logan Named as Successor

Costa Mesa, Calif., May 5, 2004 - Global Dosimetry Solutions, Inc., (GDS) a leading international provider of dosimetry services (analytical determination of exposure to ionizing radiation), is pleased to announce the appointment of Thomas Logan as its Chief Executive Officer (CEO). Logan joins GDS after having served as its Chief Transition Officer in conjunction with the purchase of GDS by American Capital Strategies Ltd. (NASDAQ: ACAS) from Valeant Pharmaceutical. With more than 20 years of experience in global manufacturing, Logan has held senior operating and financial roles within the contract manufacturing, consumer products and integrated energy industries. He is the former Chairman of the Board of the Association for Financial Professionals, and a current Board member of the New Piper Aircraft Corporation. Logan holds a Bachelor of Science degree and a Master's degree in business from Cornell University.

The new appointment was made following the company's announcement that Sandra (Sandi) Nemecek, the company's President and a founding employee plans to retire at the end of this year. "I have been preparing for this day for some time," said Nemecek. "Now that GDS is thriving as an independent company, I can't think of a better legacy for my retirement."

Nemecek began her career with GDS in 1970 and rose through the ranks. In 1978, Sandi accepted the opportunity to manage a small product line called "Dosimetry" located in Cleveland Ohio. In 1985, she relocated the business to the current location in Costa Mesa. Throughout her 34-year tenure, Sandi has enjoyed enormous success in building the company from a small product line into a dominant, global dosimetry service. "I have great confidence in Tom and am pleased that he has accepted the position of CEO," said Nemecek. "I have worked closely with him for the past six months, and we will continue to work closely together to ensure a seamless transition."

"Sandi has been a key contributor to the success of GDS - her experience and guidance in the business along with her excellent reputation in the marketplace have been instrumental in making the company what it is today," said Robert Klein, Managing Director of American Capital. "Tom brings tremendous experience in managing high-volume industrial businesses, has extensive international experience and a great leadership style, which will serve our customers and employees well," Klein continued. "We are grateful for Sandi's contribution, and look forward to continued growth under Tom's leadership."

Global Dosimetry Solutions, based in Irvine, California, is one of the world's largest providers of radiation dosimetry services. GDS offers a full range of services for measuring ionizing radiation primarily through film, thermoluminescent and track etch technologies. Since early 1970, the company has continually provided state-of-the-art personal radiation monitoring services to hospitals, medical and dental offices, university and national laboratories, nuclear power plants and other industries. GDS provides services to more than 500,000 people globally. Global Dosimetry Solutions is majority owned by American Capital Strategies, Ltd. (NASDAQ: ACAS), a $3.5 billion investment fund headquartered in Bethesda, Maryland. For more information, please visit: www.dosimetry.com.

American Capital is a publicly traded buyout and mezzanine found with capital resources in excess of $2.7 billion. American Capital is an investor in and sponsor of management and employee buyouts; invests in private equity sponsored buyouts, and provides capital directly to private and small public companies. American Capital provides senior debt, mezzanine debt and equity to fund growth, acquisitions and recapitalizations.

Companies interested in learning more about American Capital's flexible financing should contact Mark Opel, Principal, at (800) 248-9340, or visit their website.